Both proteasomes and lysosomes degrade the activated erythropoietin receptor

Blood

Volumn 105, Issue 2, 2005, Pages 600-608

  Walrafen, Pierre ^b   Verdier, Frédérique ^b   Kadri, Zahra ^b   Chrétien, Stany ^b   Lacombe, Catherine ^b   Mayeux, Patrick ^a  

^a INSTITUT COCHIN   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEASOME;

ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; HALF LIFE TIME; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTERNALIZATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; RECEPTOR DOWN REGULATION; UBIQUITINATION; WESTERN BLOTTING;

EID: 11244273938     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1216     Document Type: Article

References (53)

1. Lacombe C, Mayeux P. Erythropoietin (Epo) receptor and Epo mimetics. Adv Nephrol Necker Hosp. 1999;29:177-189.
2. Yoshimura A, D'Andrea AD, Lodish HF. Friend spleen focus-forming virus glycoprotein gp55 interacts with the erythropoietin receptor in the endoplasmic reticulum and affects receptor metabolism. Proc Natl Acad Sci U S A. 1990;87:4139-4143.
3. Neumann D, Wikstrom L, Watowich SS, Lodish HF. Intermediates in degradation of the erythropoietin receptor accumulate and are degraded in lysosomes. J Biol Chem. 1993;268:13639-13649.
4. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell. 2001;8:1327-1338.
5. Constantinescu SN, Ghaffari S, Lodish HF. The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab. 1999;10:18-23.
6. Klingmuller U, Lorenz U, Cantley LC, Neel BG, Lodish HF. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell. 1995;80:729-738.
7. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol. 1996;16:6985-6992.
8. Yoshimura A, Ohkubo T, Kiguchi T, et al. A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 1995;14:2816-2826.
9. Verdier F, Chretien S, Muller O, et al. Proteasomes regulate erythropoietin receptor and signal transducer and activator of transcription 5 (STAT5) activation: possible involvement of the ubiquitinated cis protein. J Biol Chem. 1998;273:28185-28190.
10. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 2000;275: 29338-29347.
11. Beckman DL, Lin LL, Quinones ME, Longmore GD. Activation of the erythropoietin receptor is not required for internalisation of bound erythropoietin. Blood. 1999;94:2667-2675.
12. Verdier F, Walrafen P, Hubert N, et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem. 2000;275:18375-18381.
13. Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F. Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 1997;17:4991-5000.
14. Dahlen DD, Broudy VC, Drachman JG. Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood. 2003;102:102-108.
15. Duprez V, Cornet V, Dautry-Varsat A. Down-regulation of high affinity interleukin 2 receptors in a human tumor T cell line: interleukin 2 increases the rate of surface receptor decay. J Biol Chem. 1988;263:12860-12865.
16. Strous GJ, Gent J. Dimerization, ubiquitylation and endocytosis go together in growth hormone receptor function. FEBS Lett. 2002;529:102-109.
17. van Kerkhof P, Covers R, Alves dos Santos CM, Strous GJ. Endocytosis and degradation of the growth hormone receptor are proteasome-dependent. J Biol Chem. 2000;275:1575-1580.
18. van Kerkhof P, Strous GJ. The ubiquitin-proteasome pathway regulates lysosomal degradation of the growth hormone receptor and its ligand. Biochem Soc Trans. 2001;29:488-493.
19. Lamaze C, Dujeancourt A, Baba T, Lo CG, Benmerah A, Dautry-Varsat A. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell. 2001;7:661-671.
20. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains. J Cell Biol. 1995;129: 55-64.
21. Rocca A, Lamaze C, Subtil A, Dautry-Varsat A. Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. Mol Biol Cell. 2001;12:1293-1301.
22. Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, Li CC. Involvement of the ubiquitin-proteasome pathway in the degradation of non-tyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol. 2000;165: 6372-6380.
23. Yu A, Malek TR. The proteasome regulates receptor-mediated endocytosis of interleukin-2. J Biol Chem. 2001;276:381-385.
24. Komatsu N, Nakauchi H, Miwa A, et al. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res. 1991;51:341-345.
25. Verdier F, Chrétien S, Billat C, Gisselbrecht S, Lacombe C, Mayeux P. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2: an alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J Biol Chem. 1997;272:26173-26178.
26. Mayeux P, Billat C, Jacquot R. The erythropoietin receptor of rat erythroid progenitor cell: characterization and affinity cross-linkage. J Biol Chem. 1987;262:13985-13990.
27. Mayeux P, Casadevall N, Lacombe C, Muller O, Tambourin P. Solubilization and hydrodynamic characteristics of the erythropoietin receptor: evidence for a multimeric structure. Eur J Biochem. 1990;194:271-278.
28. Wang Y, Pennock S, Chen X, Wang Z. Internalization of inactive EGF receptor into endosomes and the subsequent activation of endosome-associated EGF receptors. Sci STKE. 2002;161: PL17.
29. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
30. Dusanter-Fourt I, Casadevall N, Lacombe C, et al. Erythropoietin induces the tyrosine phosphorylation of its own receptor in human erythropoietin- responsive cells. J Biol Chem. 1992;267:10670-10675.
31. Reijngoud DJ, Oud PS, Kas J, Tager JM. Relationship between medium pH and that of the lysosomal matrix as studied by two independent methods. Biochim Biophys Acta. 1976;448:290-302.
32. Subtil A, Galdarov I, Kobylarz K, Lampson MA, Keen JH, McGraw TE. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc Natl Acad Sci USA. 1999;96:6775-6780.
33. Rodal SK, Skretting G, Garred O, Vilhardt F, van Deurs B, Sandvig K. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell. 1999;10:961-974.
34. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645-648.
35. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179-185.
36. Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002;4:556-564.
37. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene. 2000;19:810-820.
38. Schmidt MH, Furnari FB, Cavenee WK, Bogler O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. Proc Natl Acad Sci U S A. 2003;100:6505-6510.
39. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93:440-446.
40. Ward AC, van Aesch YM, Schelen AM, Touw IP. Defective internalization and sustained activation of truncated granulocyte colony-stimulating factor receptor found in severe congenital neutropenia/acute myeloid leukemia. Blood. 1999;93:447-458.
41. Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol. 2003;13:29-40.
42. Bouscary D, Pene F, Claessens YE, et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood. 2003;101:3436-3443.
43. Alves dos Santos CM, ten Broeke T, Strous GJ. Growth hormone receptor ubiquitination, endocytosis, and degradation are independent of signal transduction via Janus kinase 2. J Biol Chem. 2001;276:32635-32641.
44. Buttle DJ, Murata M, Knight CG, Barrett AJ. CA074 methyl ester: a proinhibitor for intracellular cathepsin B. Arch Biochem Biophys. 1992;299: 377-380.
45. Friedman AD, Nimbalkar D, Quelle FW. Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation. J Biol Chem. 2003;278: 26851-26861.
46. Mosesson Y, Shtiegman K, Katz M, et al. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem. 2003;278:21323-21326.
47. Strous GJ, van Kerkhof P. The ubiquitin-proteasome pathway and the regulation of growth hormone receptor availability. Mol Cell Endocrinol. 2002;197:143-151.
48. Martinez-Moczygemba M, Huston DP. Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization. J Clin Invest. 2001;108:1797-1806.
49. Levkowitz G, Waterman H, Zamir E, et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 1998;12:3663-3674.
50. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interteron-alpha receptor. EMBO J. 2003;22: 5480-5490.
51. Bakker WJ, Blazquez-Domingo M, Kolbus A, et al. FoxO3a regulates erythroid differentiation and induces BTG1, an activator of protein arginine methyl transferase 1. J Cell Biol. 2004;164:175-184.
52. Zermati Y, Garrido C, Amsellem S, et al. Caspase activation is required for terminal erythroid differentiation. J Exp Med. 2001;193:247-254.
53. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991; 77:2583-2590.